Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Stemmer SM, Steiner M, Rizel S, Ben-Baruch N, Uziely B, Jakubowski DM, Baron J, Shak S, Soussan-Gutman L, Bareket-Samish A, Fried G, Rosengarten O, Itay A, Nisenbaum B, Katz D, Leviov M, Tokar M, Liebermann N, Geffen DB. Stemmer SM, et al. Among authors: nisenbaum b. NPJ Breast Cancer. 2019 Nov 8;5:41. doi: 10.1038/s41523-019-0137-3. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31728408 Free PMC article.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators. Zielinski C, et al. Among authors: nisenbaum b. Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5. Lancet Oncol. 2016. PMID: 27501767 Clinical Trial.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, Fried G, McCullough D, Svedman C, Shak S, Liebermann N, Ben-Baruch N. Stemmer SM, et al. Among authors: nisenbaum b. NPJ Breast Cancer. 2017 Sep 8;3:32. doi: 10.1038/s41523-017-0033-7. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28900632 Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Maddala T, Klang SH, Zidan J, Ryvo L, Kaufman B, Evron E, Karminsky N, Goldberg H, Shak S, Liebermann N. Stemmer SM, et al. Among authors: nisenbaum b. NPJ Breast Cancer. 2017 Sep 8;3:33. doi: 10.1038/s41523-017-0034-6. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28900633 Free PMC article.
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Reinhorn D, Kuchuk I, Shochat T, Nisenbaum B, Sulkes A, Hendler D, Rotem O, Tsoref D, Olitzky O, Goldvaser H, Sarfaty M, Neiman V, Prus J, Gottfried M, Yust-Katz S, Yerushalmi R. Reinhorn D, et al. Among authors: nisenbaum b. Breast Cancer Res Treat. 2021 Jul;188(2):379-387. doi: 10.1007/s10549-021-06198-4. Epub 2021 Mar 27. Breast Cancer Res Treat. 2021. PMID: 33772709
Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
Smith I, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Saracchini S, Nisenbaum B, Pelaez I, Duenne AA, Pritchard KI. Smith I, et al. Among authors: nisenbaum b. Breast Cancer Res Treat. 2011 Nov;130(1):133-43. doi: 10.1007/s10549-011-1695-8. Epub 2011 Aug 10. Breast Cancer Res Treat. 2011. PMID: 21830015 Clinical Trial.
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. Guerrero-Zotano Á, et al. Clin Cancer Res. 2023 Apr 14;29(8):1557-1568. doi: 10.1158/1078-0432.CCR-22-2206. Clin Cancer Res. 2023. PMID: 36749874 Free PMC article. Clinical Trial.
12 results